crofelemer 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
polymers	4744	148465-45-6

Description:

Molecule

Description

Synonyms:

crofelemer
fulyzaq

an antisecretory antidiarrheal

Molecular weight:
Formula: None
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 2012	FDA	SALIX PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A07XA06	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS OTHER ANTIDIARRHEALS Other antidiarrheals
FDA EPC	N0000178374	Antidiarrheal

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-infective diarrhea	indication	69980003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
CANALEVIA-CA1	Jaguar Animal Health	1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
125MG	MYTESI	NAPO PHARMS INC	N202292	Dec. 31, 2012	RX	TABLET, DELAYED RELEASE	ORAL	8962680	Oct. 31, 2031	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
125MG	MYTESI	NAPO PHARMS INC	N202292	Dec. 31, 2012	RX	TABLET, DELAYED RELEASE	ORAL	9585868	Oct. 31, 2031	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cystic fibrosis transmembrane conductance regulator	Ion channel	P13569	CFTR_HUMAN	INHIBITOR	IC50	5.16		WOMBAT-PK	DRUG LABEL
Anoctamin-1	Ion channel	Q5XXA6	ANO1_HUMAN	INHIBITOR	IC50	5.19		WOMBAT-PK	DRUG LABEL

External reference:

ID	Source
D03605	KEGG_DRUG
4032216	VUID
N0000186781	NUI
4032216	VANDF
CHEMBL2108184	ChEMBL_ID
C546704	MESH_SUPPLEMENTAL_RECORD_UI
7453	IUPHAR_LIGAND_ID
DB04941	DRUGBANK_ID
PY79D6C8RX	UNII
1364449	RXNORM
196738	MMSL
29029	MMSL
d07940	MMSL
014824	NDDF
725534007	SNOMEDCT_US
763594007	SNOMEDCT_US
C2744960	UMLSCUI
17397714	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MYTESI	HUMAN PRESCRIPTION DRUG LABEL	1	70564-802	TABLET, COATED	125 mg	ORAL	NDA	24 sections